Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2020-12-02 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
控股股东及一致行动人关于不存在为发行对象作出保底保收益承诺等事项的声明和承诺
Regulatory Filings Classification · 95% confidence The document is a statement from the controlling shareholders and related parties of 瑞康医药集团股份有限公司 regarding the absence of guaranteed returns or commitments related to a non-public stock issuance. It references compliance with specific securities regulations and includes a formal declaration and commitment. The document is short (626 characters) and serves as an announcement or declaration rather than a detailed financial report or filing. It does not contain financial statements, audit information, or detailed management discussion. It is not a report but a regulatory announcement related to securities issuance compliance. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-12-02 Chinese
公司与国金证券股份有限公司关于非公开发行股票申请文件反馈意见的回复
Capital/Financing Update Classification · 95% confidence The document is a detailed response to feedback from the China Securities Regulatory Commission regarding a non-public stock issuance application by 瑞康医药集团股份有限公司 (Ruikang Pharmaceutical Group Co., Ltd.). It includes extensive disclosures about stock pledges, shareholder information, financing details, compliance with regulatory requirements, and assurances from controlling shareholders. The content is focused on regulatory compliance and detailed explanations related to a capital raising event (non-public stock issuance). This aligns with the category of Capital/Financing Update (CAP), as it involves updates and disclosures about the company's financing activities and capital structure changes. The document is lengthy (15,000 characters) and contains substantive content, not merely an announcement or certification, so it is not RPA or RNS. Therefore, the appropriate classification is CAP with high confidence.
2020-12-02 Chinese
关于控股股东及一致行动人不减持公司股票的承诺
Major Shareholding Notification Classification · 95% confidence The document is a public announcement from Ruikang Pharmaceutical Group Co., Ltd. regarding a commitment by the controlling shareholders and persons acting in concert not to reduce their holdings of the company's stock. It includes a pledge letter with specific terms about shareholding and non-reduction plans. The content focuses on shareholding commitments and insider shareholding behavior rather than financial results, management changes, or regulatory filings. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes or commitments related to significant share ownership levels. The document is short (675 characters) and does not contain financial statements or detailed financial data, so it is not an Annual Report or Earnings Release. It is not a Director's Dealing report since it is about a commitment not to sell shares rather than actual transactions. Therefore, the best classification is MRQ with high confidence.
2020-12-02 Chinese
北京市金杜律师事务所关于公司非公开发行A股股票的补充法律意见书（一）
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding a company's non-public issuance of A-shares. It discusses compliance with securities laws, shareholder information, issuance plans, and legal confirmations related to a specific capital raising event. The content focuses on legal opinions and confirmations about the issuance process rather than financial results or management commentary. It is not an annual or quarterly report, earnings release, or management discussion. It is also not a simple announcement or certification but a substantive legal report related to capital issuance. Therefore, the document fits best under the category of Capital/Financing Update (CAP), as it provides detailed legal and compliance information about a capital raising transaction.
2020-12-02 Chinese
第四届董事会第九次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the ninth meeting of the fourth board of directors of Ruikang Pharmaceutical Group Co., Ltd. It includes the approval of the 2020 third quarter report and an investment decision. The document is short (1092 characters) and primarily serves as a notice of board meeting decisions rather than the full quarterly report itself. It does not contain detailed financial statements or substantive financial data but references the report and investment decisions. Therefore, it is best classified as a Board/Management Information (MANG) filing, which covers announcements of board decisions and management matters.
2020-10-30 Chinese
2020年第三季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2020 Third Quarter Report" of 瑞康医药集团股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and management commentary on financial performance and changes during the quarter. The length is substantial (15,000 characters), and it includes actual financial statements and substantive financial analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2020
2020-10-30 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.